Inhalation Toxicology Testing Services Market Revenue to Attain USD 23.63 Bn by 2033

24 Sep 2025

Share :

Table of Content

1. Inhalation Toxicology Testing Services Market Revenue and Trends 2025 to 2033 2. Unlocking the Growth Potential of the Inhalation Toxicology Testing Services Market? 3. Segment Insights: 4. Regional Insights 5. Inhalation Toxicology Testing Services Market Coverage 6. Inhalation Toxicology Testing Services Market Key Players

Inhalation Toxicology Testing Services Market Revenue and Trends 2025 to 2033

The global inhalation toxicology testing services market revenue reached USD 14.64 billion in 2025 and is predicted to attain around USD 23.63 billion by 2033 with a CAGR of 6.17%. The market growth is attributed to increasing regulatory pressure, rising prevalence of respiratory diseases, growing adoption of inhaled therapies and drug delivery systems, and demand for safer chemical products and occupational/environmental risk assessments.

Unlocking the Growth Potential of the Inhalation Toxicology Testing Services Market?

Several factors are influencing the growth and potential within the market for inhalation toxicology testing services. These include stringent and evolving regulatory standards from bodies like the FDA, EMA, and OECD, which mandate inhalation toxicity data for new inhaled products (such as drugs, agrochemicals, industrial chemicals, and consumer goods). Ongoing research and development in respiratory diseases, which require inhaled or aerosolized drugs, is also a key driver.

Furthermore, increasing awareness of worker and environmental safety, particularly concerning fine herbal or chemical particulates and aerosols in industrial, agricultural, and chemical sectors, are influencing the growth of the market. Technological advancements, such as more precise aerosol generation, GLP-compliant testing in exposure atmosphere systems, and the development of alternative in vitro and animal-free models that reduce costs, also contribute to market growth.

Segment Insights:

• By service/study type, the repeated-dose inhalation toxicity segment dominated the market because it provides comprehensive safety data by evaluating the effects of repeated or prolonged exposure to inhaled substances over varying durations.
• By exposure mode/atmosphere, the aerosol (particulate)-controlled MMAD/PSD segment dominated the inhalation toxicology testing services market in 2024, as it is the most suitable inhalation route, involving airborne fine particulate matter and a series of detailed tests required to assess toxicity. This control ensures reliable and reproducible results in toxicity assessments, which are essential for regulatory compliance and safety evaluations of inhaled drugs, chemicals, and environmental pollutants. 
• By biological model, the in vivo segment dominated this market in 2024, as regulatory agencies continue to mandate live animal data for many endpoints, particularly for complex inhalation exposure, deposition, metabolism, and systemic effects. This approach allows for the assessment of complex interactions among respiratory, immune, and systemic responses that cannot be fully captured by in vitro or computational models.
• By endpoint/output, the histopathology & pulmonary pathology segment led the market, because it provides critical microscopic insights into tissue-level changes and damage caused by inhaled substances, offering a direct measure of toxic effects on the respiratory system.
• By end-market/application, the pharmaceutical segment dominated the market in 2024, as inhaled drugs and pulmonary therapeutics require extensive and comprehensive toxicology testing to support an IND/NDA, registration, and particularly for the development of new inhaled molecules or biologics.

Regional Insights

North America led the inhalation toxicology testing services market with the largest share in 2024. This is mainly due to its well-established pharma and biotech industries, robust regulatory frameworks, and significant R&D investments. Stringent testing regulations for inhalation therapies and chemicals, enforced by U.S. federal agencies such as the FDA, have facilitated the early adoption of these testing services.

Asia Pacific is expected to experience rapid growth in the upcoming period, driven by rising healthcare expenditures, expanding pharmaceutical and biotech sectors in major countries like China, India, and Japan, and the development of regulatory frameworks that align with international safety standards. The increasing prevalence of respiratory diseases, growing interest in inhaled drug development, industrialization, pollution, and the need for a domestic testing infrastructure are all boosting the demand for these services within the region.

Inhalation Toxicology Testing Services Market Coverage

Inhalation Toxicology Testing Services Market Key Players

• Laboratory Corporation of America Holdings
• Charles River Laboratories, Inc.
• Eurofins Scientific
• Bureau Veritas
• Envigo
• Evotec AG
• Merck KGaA
• SGS Group
• Pharmaceutical Product Development
• LLC (PPD)
• WuXi AppTec

Recent Development:

• In January 2025, Inhalation Sciences (ISAB) announced plans to launch its enhanced XposeALI in vitro exposure module with microperfusion, following development in 2024 and final validation in partnership with a global pharmaceutical client. The upgrade enables a more physiologically relevant simulation of the effects of inhaled substances on lung tissue. XposeALI® already offers proven delivery of diverse aerosols to airway cell cultures via ISAB’s PreciseInhale® platform.
  (Source: https://news.cision.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6845

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344